Primary Immunodeficiency and Immune Dysregulation
Pharming Technologies B.V. focuses clinical research on primary immunodeficiency disorders, with particular attention to common variable immunodeficiency and related immune dysregulation conditions. Its studies address the clinical burden of abnormal immune function in both adult and pediatric populations.
- Common variable immunodeficiency
- Immune dysregulation
- Primary immunodeficiency
Research in this area includes ongoing work in patients with clinically significant immune dysfunction across multiple age groups.
Activated Phosphoinositide 3-Kinase Delta Syndrome
The sponsor has a strong therapeutic interest in activated phosphoinositide 3-kinase delta syndrome (APDS), a rare immune disorder associated with dysregulated immune signaling. Clinical activity spans pediatric patients as well as individuals with established immune dysregulation.
- APDS
- Immune signaling abnormalities
- Pediatric immunology
This area includes research in children from early childhood through school age, reflecting a sustained focus on rare immune-mediated disease.
Pediatric Immunology
Pharming Technologies B.V. conducts research in pediatric immunology, with studies involving children affected by APDS and related immune disorders. The clinical portfolio includes younger pediatric populations, highlighting interest in age-specific immune disease management.
- Children with APDS
- Pediatric patients
- Immune disorder care
These studies extend across early childhood and later childhood cohorts, supporting therapeutic development in rare immune conditions affecting children.
Pharmacology and Clinical Pharmacokinetics
The sponsor also maintains research interest in pharmacology and clinical pharmacokinetics related to leniolisib, including studies in healthy volunteers and individuals with altered organ function. This work supports understanding of how the therapy behaves across different patient groups.
- Bioavailability
- Hepatic function
- Drug-drug interaction
These investigations complement the sponsor’s immune-disease portfolio by addressing treatment behavior in varied clinical settings.
